Abstract-We measured the cleavage of angiotensin I (Ang I) metabolites by angiotensin I-converting enzyme (ACE) in cultured cells and examined how they augment actions of bradykinin B 2 receptor agonists. Monolayers of Chinese hamster ovary cells transfected to stably express human ACE and bradykinin B 2 receptors coupled to green fluorescent protein (B 2 GFP) or to express only coupled B 2 GFP receptors. We used 2 ACE-resistant bradykinin analogues to activate the B 2 receptors. We used high-performance liquid chromatography to analyze the peptides cleaved by ACE on cell monolayers and found that Ang 1-9 was hydrolyzed 18ϫ slower than Ang I and Ϸ30% slower than Ang 1-7. Ang 1-7 was cleaved to Ang 1-5. Although mol/L concentrations of slowly cleaved substrates Ang 1-7 and Ang 1-9 inhibit ACE, they resensitize the desensitized B 2 GFP receptors in nmol/L concentration, independent of ACE inhibition. This is reflected by release of arachidonic acid through a mechanism involving cross-talk between ACE and B 2 receptors. When ACE was not expressed, the Ang 1-9, Ang 1-7 peptides were inactive. Inhibitors of protein kinase C-␣, phosphatases and Tyr-kinase blocked this resensitization activity, but not basal B 2 activation by bradykinin. 
A ngiotensin I-converting enzyme (ACE) inhibitors are used by tens of millions of patients to block conversion of angiotensin I (Ang I) to Ang II and inactivation of bradykinin; the latter contributes significantly to the beneficial effects. [1] [2] [3] [4] After ACE inhibitors increase Ang I concentration, it can be converted to derivatives such as Ang 1-9 and Ang 1-7. 5, 6 Ang 1-7 actively antagonizes the vasoconstrictor and proliferative effects of Ang II. 7, 8 Ang 1-9, believed to be inactive until converted by ACE to the active Ang 1-7, which is subsequently inactivated by release of the C-terminal dipeptide to form Ang 1-5. The heptapeptide has its own receptor, its specific activities differ from those of Ang II, 9, 10 and it also enhances the activity of bradykinin on its B 2 receptors. 11, 12 The major enzymes that cleave Ang I to derivatives other than Ang II are ACE2 [13] [14] [15] and deamidase or cathepsin A. 12 ACE2 is a carboxypeptidase instead of a peptidyl dipeptidase like ACE. 16 ACE2 hydrolyzes Ang II orders of magnitude faster than Ang I. 15 ACE2 generates Ang 1-7 by releasing the C-terminal Phe 8 of Ang II much more efficiently than cleaving the C-terminal Leu 10 of Ang I (Figure 1 ). ACE2 commanded much attention because a genetically determined lack of the enzyme can block normal heart development 13, 14 and because of its identity with the corona virus receptor. 13 Ang I is rapidly converted to Ang 1-9 by deamidase or cathepsin A, found in the heart and throughout the body. 12 A carboxypeptidase A-type enzyme 17 also releases Ang 1-9, which inhibits ACE at relatively high concentrations. 11 To determine whether Ang 1-9 is active per se or it becomes active only after conversion to Ang 1-7 under our conditions, we examined the metabolism of Ang I, Ang 1-9, and Ang 1-7 in stably transfected Chinese hamster ovary (CHO) cells that express human ACE and human bradykinin B 2 receptors coupled to green fluorescent protein (B 2 GFP). We then used the membranes of living cells to establish that Ang I cleavage products, in addition to potentiating bradykinin activity, 12, 18, 19 also resensitized the B 2 GFP receptors desensitized by agonist. We found that they were active at much lower concentrations than suggested by their IC 50 values for ACE. Because ACE, or kininase II, is a major bradykinin inactivator, 3 we used an ACE-resistant bradykinin analogue (BKan) 20 and synthesized another, didansyl-lysylbradykinin (DidnsKBK), as B 2 GFP receptor agonists.
Enzyme Purification
Human renal ACE was purified from human cadaver kidneys. 21 Approval for use of human tissue was granted by the internal review board of our university. 
Measurement of [ 3 H]Arachidonic Acid

B 2 GFP Expression Construct
Production and subcloning of the B 2 GFP fusion protein was done in 2 steps. First, the coding sequence of GFP was altered by polymerase chain reaction (PCR) purification to introduce an amino terminal XhoI restriction site and a carboxyl-terminal XbaI restriction site following the stop codon.
The amplified fragment of GFP digested with XhoI and XbaI was ligated to the pcDNA3 expression vector digested with XhoI and XbaI. To obtain the B 2 GFP fusion protein, the sequence of B 2 receptor was amplified by PCR. HindIII restriction site and a partial Kozak site were introduced in front of the initiator Met of the B 2 receptor, and XbaI restriction site was introduced in front of the stop codon of B 2 receptor. Finally, the GFP construct in pcDNA3 was digested with XhoI and HindIII and was ligated together with the PCR product of the B 2 receptor amplification, which was also digested with XhoI and HindIII. The open reading frame representing the coding sequence of B 2 GFP was fully sequenced before its expression and analysis.
Construction of CHO/ACE-B 2 GFP Cells
The cDNA of B 2 GFP was stably transfected into CHO-K1 cells, and transfectants were selected by fluorescence-activated cell sorting. Selected clones were tested for B 2 GFP function by measuring [Ca 2ϩ ] i response to bradykinin stimulation. Cells with high expression of B 2 GFP (CHO/BG) were selected and transfected with cDNA of human ACE and the transfectants selected with geneticin. Then a clone of cells with high ACE activity, CHO/ACE-BG (CHO/ABG), was chosen.
Synthesis of DidnsKBK
The molecular mass of samples was determined with electron spray mass spectroscopy, corresponding closely to the calculated values for monodansyl-KBK (1421.8) and DidnsKBK (1655.1). The ␣NH 2 group in the monodansyl compound and both ␣-amino and -amino groups of Lys 1 in DidnsKBK were coupled (please see online supplement, available at http://www.hypertensionaha.org).
Hydrolysis of Lys 1 -Bradykinin, Monodansyl-KBK and DidnsKBK by ACE
Hydrolysis was assayed by incubating each of the peptides (100 mol/L) with 2 nmol/L purified human ACE in 50 mmol/L Tris-maleate buffer with 150 mmol/L NaCl, pH 7.8, at 37°C for 30 minutes. Ice-cold 5% trifluoroacetic acid (TFA) precipitated the enzyme. Percent hydrolysis was determined by changes in substrate peak area in high-performance liquid chromatography (HPLC).
Hydrolysis of Peptides by Cell Monolayers
CHO/ABG cells were grown in DMEM containing 10% FBS in 12-well plates. Cell monolayers were washed with serum-free DMEM, and 400 L serum-free DMEM containing 50 to 800 mol/L angiotensin peptide was added to each well. Plates were incubated at 37°C with shaking for appropriate times. Then 140-L aliquots were drawn and added to 70 L of 5% ice-cold TFA. Fifty-microliter aliquots were analyzed by reversed-phase HPLC. Less than 1% ACE activity was released spontaneously into the medium.
Lisinopril Titration of ACE
ACE activity on cell monolayers was titrated with the tight binding inhibitor lisinopril. Cells were grown to confluence in 12-well plates (Ϸ10 6 cells per well). After washing, 0 to 375 nmol/L lisinopril was added, and the plates were incubated with shaking at 37°C for 30 minutes. Then 50 mol/L Ang I was added and incubation was continued for 5 minutes. Hydrolysis products were analyzed.
Hydrolysis of Peptides by ACE In Vitro
For kinetics, Ang I and Ang 1-9 (50 to 800 mol/L) were incubated with 2 or 10 nmol/L of purified human ACE in 50 mmol/L Tris-maleate buffer with 150 mmol/L NaCl, pH 7.8, at 37°C. The hydrolysis products were analyzed by HPLC.
Analysis of Hydrolysis Products
Peptides and their hydrolysis products were separated on a Bondclone 10 C18 reversed-phase column (Phenomenex) with a 10% to 28% linear gradient of acetonitrile/0.05% TFA in H 2 O/0.05% TFA over 30 minutes. Products were detected at 214-nm wavelength. The cleavage of peptides followed zero-order kinetics during the assay, and amounts of peptide fragments were determined with standard peptides.
Resensitization of Bradykinin Receptors in CHO/ABG Cells
After desensitization of B 2 GFP receptors by initial exposure of cells to bradykinin or BKan to induce tachyphylaxis, 11 we assessed the 
Effect of Inhibitors on Resensitization
CHO/ABG cells were incubated with 1 of the following inhibitors: 
Hydrolysis of N-Terminally Protected BKan Analogue
To study resensitization, we synthesized a derivative of bradykinin with a bulky N terminus that would protect it from inactivation by ACE but would allow it to act as an agonist of the B 2 receptor. KBK was dansylated at its ␣NH 2 or at the ␣NH 2 and NH 2 groups of lysine (Table 1) . Whereas human ACE cleaved monodansyl-KBK at about one third the rate of KBK, DidnsKBK was only 0.4% hydrolyzed in 30 minutes. Table 2 shows that Ang I had the highest Michaelis constant (K m ; 119 mol/L) when CHO/ABG cell monolayers hydrolyzed Ang peptides, followed by Ang 1-9 (61 mol/L) and Ang 1-7 (35 mol/L). The catalytic constant (k cat ) of Ang I was also the highest (2890/min Ϫ1 ) and was 18ϫ higher than that of Ang 1-9 and 12ϫ higher than Ang 1-7. Ang 1-7 was 4ϫ less efficiently hydrolyzed (
Kinetics of Hydrolysis of Peptides by Cell Monolayers
and Ang 1-9 had the lowest specificity constant (
), Ϸ10ϫ less than that of Ang I. -9) . The k cat of ACE on the plasma membrane of intact cells was much higher than with purified enzyme, which suggests some loss of activity of during purification or a lack of negative cooperativity between the 2 active sites of ACE on the cell membrane. Also, the specificity constant (k cat /K m ) for each peptide was lower for the purified enzyme than for the cell surface enzyme (1.3 versus 2.6 mol/L/min) for Ang 1-9. The lower K m with the purified enzyme did not offset the lower k cat .
Comparison of Kinetics of Hydrolysis by Purified Human ACE and Cell Monolayers
Resensitization of B 2 GFP Receptors by Ang 1-7 and Ang 1-9
The bradykinin B 2 receptor was desensitized by pretreating CHO/ABG cells with 1 mol/L BKan, and the agonist was tested again to establish that desensitization had occurred. Ang 1-7 or Ang 1-9 was then added in concentrations varying from 1 to 10 nmol/L. Figure 2A shows [ 3 H]AA release in cells expressing B 2 GFP and ACE. The results indicate that exposure to the peptides resensitized the B 2 GFP receptor to BKan in a concentration-dependent manner. Ang 1-9 (10 nmol/L) was significantly more active than Ang 1-7 (PϽ0.01). The bradykinin B 2 receptor antagonist HOE 140 completely blocked resensitization. The expression of ACE on the cell surface was required because in CHO/BG cells lacking ACE, the B 2 receptors could not be resensitized by either Ang 1-7 or Ang 1-9 or by enalaprilat (please see online supplement). In the absence of ACE expression, the desensitized B 2 receptor remains inactive. In Figure 2B , the B 2 receptor was desensitized with 10 mol/L DidnsKBK, which is unaffected by ACE, then 1 mol/L Ang 1-9 or enalaprilat was added without adding more B 2 agonist. This treatment resensitized the receptor to release [ 3 H]AA, and HOE 140 blocked it. DidnsKBK, even at 50-mol/L concentration, did not inhibit ACE using hippuryl-his-leucine as substrate (data not shown). 
Effect of Protein Kinase C and Protein Phosphatase Inhibitors on Resensitization
Effect of Tyrosine Kinase Inhibitor on Resensitization
The tyrosine kinase inhibitor genistein also completely blocked resensitization of CHO/ABG cells by Ang 1-7, Ang 1-9, or enalaprilat (EPT) ( Figure 4 
Discussion
Although the role of angiotensin in hypertension was well established during the past century, 23 this peptide has become increasingly relevant to various pathological conditions other than hypertension. Ang II, released by ACE, acting on its angiotensin type 1 (AT 1 ) receptor is usually noxious, whereas activation of the Angiotensin type 2 (AT 2 ) receptor can counteract some of these effects, possibly through the bradykinin B 2 receptor. 24 ACE is also kininase II; 3,25 its inhibitors block the inactivation of kinins. Because of the proven and probable pathological functions of Ang II and the widely reported counter-regulatory actions of Ang 1-7, 7-9 we wished to establish how Ang II metabolites influence bradykinin activity. We included Ang 1-9 because it has not been well studied and is thought to be active only after conversion to Ang 1-7 ( Figure 1 ). Both peptides inhibited ACE 11, 19 but only in mol/L concentrations. We reported that Ang 1-7 was cleaved only by one of the active sites of ACE, by the so-called N domain and not by native testicular C domain. 19 Rice et al described that Ang 1-9 was converted more readily to Ang 1-7 by the separate recombinant C domain of ACE than by the N domain, but as shown above, they also found that Ang 1-9 was hydrolyzed much slower than Ang I. 15 Cleavage of peptides by ACE can be influenced by its high carbohydrate content; for example, the degrees of glycosylation of ACE from human lung and kidney differ. 26 Carbohydrate structures of enzymes can depend on their tissue and cellular origin.
To learn more about Ang I derivatives, we transfected CHO cells to express human ACE and bradykinin B 2 receptors. Lisinopril titration of active ACE sites on the cell surface indicated Ϸ5ϫ10 6 ACE molecules on the apical surface. Using saturation binding with labeled bradykinin, we found Ϸ1ϫ10 6 B 2 receptors per cell. This estimate assumes 2 active sites per molecule of ACE rather than an apparent single active site attributable to negative cooperativity between the 2 sites. 27, 28 We compared the rates of hydrolysis of Ang I and its derivatives by ACE in CHO cells. Ang 1-9 was converted to Ang 1-7 at a rate Ͻ6% of Ang II release with a 90% lower specificity constant. Ang 1-7 was inactivated to Ang 1-5 by ACE at a relatively low turnover rate and specificity constant (Table 1) . Thus, Ang 1-7 and Ang 1-9 are more resistant to hydrolysis by ACE than Ang I. Although Ang 1-7 and Ang 1-9 have a slow turnover rate, their K m was lower than that of Ang I but still much higher than the K m for bradykinin: 1 to 0.1 mol/L. 25, 26 Consequently, neprilysin (neutral endopeptidase 24.11) is the major enzyme that liberates Ang 1-7 from Ang I 5, 6 and ACE2, 15 and prolylcarboxypeptidase releases it from Ang II. 29 Human chymase liberates only Ang II from Ang I 30 (Table 1) .
Ang I is hydrolyzed only very slowly by ACE 2, 15 whereas deamidase (cathepsin A) converts it effectively to Ang 1-9. 12,31 Ang 1-9 is more than a poor precursor of Ang 1-7 attributable to low conversion rate by ACE; it is also an active derivative of Ang I because enhances bradykinin actions in cultured cells and resensitizes its receptor. Ang 1-9 may antagonize Ang II, just as Ang 1-7 does in laboratory animals. 7, 8 Ang 1-7 and Ang 1-9 inhibited ACE only at relatively high mol/L concentrations, but in human pulmonary endothelial cells, they increased NO release by bradykinin at a much lower concentration than the IC 50 values. 12 ACE inhibitors acted beyond ACE inhibition when they potentiated kinins in cultured cells or surviving organs. 32 ACE and B 2 can colocalize and form heterodimers. 20 These findings suggest that ACE inhibitors can function as indirect allosteric enhancers 33 of B 2 bradykinin receptor agonists by inducing conformational changes via ACE.
Indeed, because Ang 1-7 and Ang 1-9 resensitize the receptors to bradykinin, they may be endogenous allosteric enhancers for B 2 receptor agonists if ACE and B 2 are expressed in the same cells. The peptides resensitized receptors at concentrations nearer to physiological levels than their IC 50 values.
To show that resensitization of the receptors cannot be explained by blocking bradykinin inactivation, 11, 20, 32 we used ACE-resistant BKans. One ACE-resistant kinin analogue has a modified Phe 8 -Arg 9 bond; 20 in the other, we dansylated both amino groups of lysine in Lys 1 -bradykinin. The size of the peptide substrate restricts ACE activity, which drops beyond undecapeptide. 34 Because B 2 receptors are more permissive and accept N-terminally enlarged agonists, such as dextran-coupled bradykinin with intact C terminus, 35 we synthesized the DidnsKBK analogue. This modified kinin was hydrolyzed by ACE at Ͻ3% of the rate for Lys 1 -bradykinin; it was not a competitive inhibitor and was blocked by HOE 140 on the B 2 receptor. As with BKan, CHO/ABG cells desensitized to DidnsKBK were resensitized by Ang 1-9 or enalaprilat. We believe that resensitization depends on the induction of conformational changes in ACE-B 2 complex and certainly not on blocking a potential inactivation of the ACE-resistant BKans.
Inhibition of protein kinases abolished potentiation 32 and resensitization without affecting basal bradykinin activities. This process unlikely involves phosphorylation of the cytosolic portion of ACE 36 because truncating the enzyme there did not affect resensitization by enalaprilat. 20 Resensitization was blocked by inhibitors of PKC, PKC␣, tyrosine kinase, and serine phosphatases, and the findings indicate that resensitization depends on rapid phosphorylation and dephosphorylation of the receptor with PKC␣ as a key component. 37 B 2 receptor activation liberates prostaglandins and other arachidonic acid metabolites 38, 39 and involves first G␣ i protein leading to downstream activation of phospholipase A 2 . Because inhibition of PKC␣ abolished resensitization, that suggests a complex cascading signal transduction pathway, which could result in the downstream opening of a transient receptor potential channel-1 Ca 2ϩ channel. 40 
Perspectives
ACE inhibitors block Ang I conversion, enhancing its concentration as substrate for enzymes such as neprilysin or deamidase. ACE2 and prolylcarboxypeptidase convert Ang II to Ang 1-7. The well-documented effects of Ang 1-7 underscore the potential importance of Ang 1-9 as an active metabolite of Ang I. Ang 1-9 and Ang 1-7 are quite resistant to ACE on the plasma membrane of cultured cells, indicating that these peptides are relatively stable derivatives. Ang 1-7 and 1-9 potentiate bradykinin B 2 receptor agonists and resensitize the desensitized receptors to ACE-resistant kinins independent of ACE inhibition, provided human ACE and B 2 receptors are expressed. Peptides resensitized B 2 receptor similarly to enalaprilat, although Ang 1-7 and Ang 1-9 are poor ACE inhibitors. Resensitization of receptors restored their ability to react to the agonist in the medium and initiate signal transduction. The fact that serine/threonine kinase and even tyrosine kinase inhibitors can block the process without affecting basal bradykinin activity suggests different pathways of transduction leading to phospholipase A 2 activation and arachidonic acid release. ACE appears to be an "acceptor" of Ang 1-7 and Ang 1-9, which, in low concentrations, may modify the conformation of an enzyme-receptor complex. By counteracting the actions of Ang II, the angiotensin-derived peptides can enhance the therapeutic usefulness of ACE inhibitors.
